Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density.

Autor: Lundstr&oum;m, Eva, Christow, Alexander, Kersemaekers, Wendy, Svane, Gunilla, Azavedo, Edward, Söderqvist, Gunnar, Mol-Arts, Mirjam, Barkfeldt, Jan, von Shoultz, Bo, Lundström, Eva, Söderqvist, Gunnar, von Schoultz, Bo
Předmět:
Zdroj: American Journal of Obstetrics & Gynecology; Apr2002, Vol. 186 Issue 4, p717-722, 6p, 1 Black and White Photograph, 3 Charts
Abstrakt: Objective: Our purpose was to compare the effects of tibolone, continuous combined hormone replacement therapy, and placebo on mammographic breast density.Study Design: A prospective, randomized, double-blind placebo-controlled study was performed. A total of 166 postmenopausal women were equally randomized to receive tibolone 2.5 mg, estradiol 2 mg/norethisterone acetate 1 mg (E(2)/NETA), or placebo. Mammograms were performed at baseline and after 6 months of treatment. Mammographic density was quantified according to the Wolfe classification and by the percentage area of the breast that had a dense pattern.Results: An increase in mammographic density was much more common among women receiving continuous combined hormone replacement therapy (46%-50%) than among those receiving tibolone (2%-6%) and placebo (0%) treatment. The difference between E(2)/NETA and placebo was highly significant (P <.001). Treatment with tibolone did not differ from that with placebo. The relative risk of an increase in breast density for E(2)/NETA versus tibolone was found to be 8.3 (95% CI 2.7-25.0).Conclusion: An increase in mammographic density should be regarded as an unwanted side effect of hormone replacement therapy. In contrast to estrogen/progestogen treatment, tibolone seems to exert little stimulation of breast tissue. [ABSTRACT FROM AUTHOR]
Databáze: Supplemental Index
Externí odkaz: